| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K26531177 | CTRPv2 | pan-cancer | AAC | -0.035 | 0.3 |
| mRNA | MI-2 | CTRPv2 | pan-cancer | AAC | -0.049 | 0.3 |
| mRNA | LY-2157299 | CTRPv2 | pan-cancer | AAC | -0.07 | 0.3 |
| mRNA | BRD-K78574327 | CTRPv2 | pan-cancer | AAC | -0.068 | 0.3 |
| mRNA | PRIMA-1-Met | CTRPv2 | pan-cancer | AAC | -0.05 | 0.3 |
| mRNA | navitoclax:sorafenib (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.033 | 0.3 |
| mRNA | tamatinib | CTRPv2 | pan-cancer | AAC | -0.035 | 0.3 |
| mRNA | BRD-K02492147 | CTRPv2 | pan-cancer | AAC | -0.037 | 0.3 |
| mRNA | sitagliptin | CTRPv2 | pan-cancer | AAC | -0.068 | 0.3 |
| mRNA | BRD-K30019337 | CTRPv2 | pan-cancer | AAC | -0.065 | 0.3 |